Terazosin Capsule
Product Images NDC 51655-915

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 51655-915). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 915 52 Rev A 06 23)

Label for terazosin capsules, USP 2 mg, containing 30 capsules in a prescription-only package. The label includes storage instructions to keep the product at 20°-25°C (68°-77°F) and away from light, moisture, and children. The product is repackaged by Northwind Pharmaceuticals, Indianapolis, IN, with NDC 51655-915.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 01)

Chemical structure of terazosin hydrochloride dihydrate, a human prescription drug active ingredient with molecular weight 459.93, showing molecular arrangement and functional groups.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 02)

A data table comparing symptom scores and peak flow rate changes between placebo and terazosin groups across three clinical studies with varying dosages and durations. The table highlights mean baseline values, mean change percentages, sample sizes (N), and statistical significance for symptom improvement and peak flow rate increase.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 03)

Figure 1 from Study 1 presents two line graphs comparing placebo and terazosin groups over 3 months. The left graph shows mean change in total symptom score from baseline, with terazosin decreasing symptoms more than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with terazosin improvement exceeding placebo. Error bars and sample sizes (N) are indicated.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 04)

Line graph titled 'Mean Change in Total Symptom Score from Baseline' depicting results of a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis shows months (0 to 30), and the y-axis shows mean change from baseline symptom score ranging from 0 to -7. The graph indicates a rapid initial decline in symptom scores within the first 3 months followed by a stable lower symptom score, with multiple points marked as statistically significant (p ≤ 0.05). Mean baseline symptom score is noted as 10.7.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 05)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The chart shows mean change in peak flow rate (mL/sec) on the vertical axis over 30 months on the horizontal axis. Data points with error bars and significance marked by asterisks indicate changes from baseline, with mean baseline at 9.9 mL/sec. The graph tracks progression and statistical significance over time.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 06)

A table presenting mean changes in blood pressure from baseline to final visit in double-blind placebo-controlled studies. It compares placebo and terazosin effects on systolic (SBP) and diastolic blood pressure (DBP) among normotensive patients (DBP ≤ 90 mmHg) and hypertensive patients (DBP > 90 mmHg), including group sizes and mean change values.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 07)

Data table summaries adverse reactions during placebo-controlled trials of terazosin for benign prostatic hyperplasia. It lists various body systems with corresponding adverse reaction percentages for terazosin versus placebo groups, including categories like cardiovascular, nervous, respiratory, and urogenital systems.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 08)

A data table titled 'Discontinuation During Placebo-Controlled Trials Benign Prostatic Hyperplasia' comparing adverse event discontinuation rates between Terazosin (N=636) and placebo (N=360). It details percentages for body systems including body as a whole, cardiovascular, digestive, nervous, respiratory, special senses, and urogenital, listing specific symptoms like fever, headache, postural hypotension, syncope, nausea, dizziness, vertigo, dyspnea, blurred vision, and urinary tract infection.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 09)

Table listing adverse reactions during placebo-controlled hypertension trials comparing terazosin (859 participants) and placebo (506 participants) across various body systems, showing percentages of occurrence for symptoms such as asthenia, headache, palpitations, nausea, dizziness, and blurred vision, with some marked as statistically significant.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 10)

Table showing discontinuation rates during placebo-controlled trials for hypertension comparing terazosin (N=859) and placebo (N=506). It lists body systems with associated symptoms and corresponding discontinuation percentages for each treatment group, including symptoms like asthenia, headache, palpitations, dizziness, and blurred vision.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 11)

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 12)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.